Cargando…
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124924/ https://www.ncbi.nlm.nih.gov/pubmed/35704976 http://dx.doi.org/10.1016/j.ejca.2022.04.036 |
_version_ | 1784711833134825472 |
---|---|
author | Pinato, David J. Ferrante, Daniela Aguilar-Company, Juan Bower, Mark Salazar, Ramon Mirallas, Oriol Sureda, Anna Bertuzzi, Alexia Brunet, Joan Lambertini, Matteo Maluquer, Clara Pedrazzoli, Paolo Biello, Federica Lee, Alvin J.X. Sng, Christopher C.T. Liñan, Raquel Rossi, Sabrina Carmona-García, M.Carmen Sharkey, Rachel Eremiev, Simeon Rizzo, Gianpiero Bain, Hamish DC. Yu, Tamara Cruz, Claudia A. Perachino, Marta Saoudi-Gonzalez, Nadia Fort-Culillas, Roser Doonga, Kris Fox, Laura Roldán, Elisa Zoratto, Federica Gaidano, Gianluca Ruiz-Camps, Isabel Bruna, Riccardo Patriarca, Andrea Shawe-Taylor, Marianne Fusco, Vittorio Martinez-Vila, Clara Berardi, Rossana Filetti, Marco Mazzoni, Francesca Santoro, Armando Delfanti, Sara Parisi, Alessandro Queirolo, Paola Aujayeb, Avinash Rimassa, Lorenza Prat, Aleix Tabernero, Josep Gennari, Alessandra Cortellini, Alessio |
author_facet | Pinato, David J. Ferrante, Daniela Aguilar-Company, Juan Bower, Mark Salazar, Ramon Mirallas, Oriol Sureda, Anna Bertuzzi, Alexia Brunet, Joan Lambertini, Matteo Maluquer, Clara Pedrazzoli, Paolo Biello, Federica Lee, Alvin J.X. Sng, Christopher C.T. Liñan, Raquel Rossi, Sabrina Carmona-García, M.Carmen Sharkey, Rachel Eremiev, Simeon Rizzo, Gianpiero Bain, Hamish DC. Yu, Tamara Cruz, Claudia A. Perachino, Marta Saoudi-Gonzalez, Nadia Fort-Culillas, Roser Doonga, Kris Fox, Laura Roldán, Elisa Zoratto, Federica Gaidano, Gianluca Ruiz-Camps, Isabel Bruna, Riccardo Patriarca, Andrea Shawe-Taylor, Marianne Fusco, Vittorio Martinez-Vila, Clara Berardi, Rossana Filetti, Marco Mazzoni, Francesca Santoro, Armando Delfanti, Sara Parisi, Alessandro Queirolo, Paola Aujayeb, Avinash Rimassa, Lorenza Prat, Aleix Tabernero, Josep Gennari, Alessandra Cortellini, Alessio |
author_sort | Pinato, David J. |
collection | PubMed |
description | BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. RESULTS: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). CONCLUSIONS: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer. |
format | Online Article Text |
id | pubmed-9124924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91249242022-05-23 Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer Pinato, David J. Ferrante, Daniela Aguilar-Company, Juan Bower, Mark Salazar, Ramon Mirallas, Oriol Sureda, Anna Bertuzzi, Alexia Brunet, Joan Lambertini, Matteo Maluquer, Clara Pedrazzoli, Paolo Biello, Federica Lee, Alvin J.X. Sng, Christopher C.T. Liñan, Raquel Rossi, Sabrina Carmona-García, M.Carmen Sharkey, Rachel Eremiev, Simeon Rizzo, Gianpiero Bain, Hamish DC. Yu, Tamara Cruz, Claudia A. Perachino, Marta Saoudi-Gonzalez, Nadia Fort-Culillas, Roser Doonga, Kris Fox, Laura Roldán, Elisa Zoratto, Federica Gaidano, Gianluca Ruiz-Camps, Isabel Bruna, Riccardo Patriarca, Andrea Shawe-Taylor, Marianne Fusco, Vittorio Martinez-Vila, Clara Berardi, Rossana Filetti, Marco Mazzoni, Francesca Santoro, Armando Delfanti, Sara Parisi, Alessandro Queirolo, Paola Aujayeb, Avinash Rimassa, Lorenza Prat, Aleix Tabernero, Josep Gennari, Alessandra Cortellini, Alessio Eur J Cancer Original Research BACKGROUND: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. METHODS: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. RESULTS: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). CONCLUSIONS: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer. Elsevier Ltd. 2022-08 2022-05-23 /pmc/articles/PMC9124924/ /pubmed/35704976 http://dx.doi.org/10.1016/j.ejca.2022.04.036 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Research Pinato, David J. Ferrante, Daniela Aguilar-Company, Juan Bower, Mark Salazar, Ramon Mirallas, Oriol Sureda, Anna Bertuzzi, Alexia Brunet, Joan Lambertini, Matteo Maluquer, Clara Pedrazzoli, Paolo Biello, Federica Lee, Alvin J.X. Sng, Christopher C.T. Liñan, Raquel Rossi, Sabrina Carmona-García, M.Carmen Sharkey, Rachel Eremiev, Simeon Rizzo, Gianpiero Bain, Hamish DC. Yu, Tamara Cruz, Claudia A. Perachino, Marta Saoudi-Gonzalez, Nadia Fort-Culillas, Roser Doonga, Kris Fox, Laura Roldán, Elisa Zoratto, Federica Gaidano, Gianluca Ruiz-Camps, Isabel Bruna, Riccardo Patriarca, Andrea Shawe-Taylor, Marianne Fusco, Vittorio Martinez-Vila, Clara Berardi, Rossana Filetti, Marco Mazzoni, Francesca Santoro, Armando Delfanti, Sara Parisi, Alessandro Queirolo, Paola Aujayeb, Avinash Rimassa, Lorenza Prat, Aleix Tabernero, Josep Gennari, Alessandra Cortellini, Alessio Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
title | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
title_full | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
title_fullStr | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
title_full_unstemmed | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
title_short | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
title_sort | vaccination against sars-cov-2 protects from morbidity, mortality and sequelae from covid19 in patients with cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124924/ https://www.ncbi.nlm.nih.gov/pubmed/35704976 http://dx.doi.org/10.1016/j.ejca.2022.04.036 |
work_keys_str_mv | AT pinatodavidj vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT ferrantedaniela vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT aguilarcompanyjuan vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT bowermark vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT salazarramon vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT mirallasoriol vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT suredaanna vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT bertuzzialexia vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT brunetjoan vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT lambertinimatteo vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT maluquerclara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT pedrazzolipaolo vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT biellofederica vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT leealvinjx vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT sngchristopherct vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT linanraquel vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT rossisabrina vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT carmonagarciamcarmen vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT sharkeyrachel vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT eremievsimeon vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT rizzogianpiero vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT bainhamishdc vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT yutamara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT cruzclaudiaa vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT perachinomarta vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT saoudigonzaleznadia vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT fortculillasroser vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT doongakris vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT foxlaura vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT roldanelisa vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT zorattofederica vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT gaidanogianluca vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT ruizcampsisabel vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT brunariccardo vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT patriarcaandrea vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT shawetaylormarianne vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT fuscovittorio vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT martinezvilaclara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT berardirossana vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT filettimarco vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT mazzonifrancesca vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT santoroarmando vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT delfantisara vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT parisialessandro vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT queirolopaola vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT aujayebavinash vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT rimassalorenza vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT prataleix vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT tabernerojosep vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT gennarialessandra vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT cortellinialessio vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer AT vaccinationagainstsarscov2protectsfrommorbiditymortalityandsequelaefromcovid19inpatientswithcancer |